Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spit test could reveal gum disease secrets

NCT ID NCT07262606

Knowledge-focused Sponsor: Ömer Faruk Okumuş Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a protein called Mitofusin-1 in saliva to see if it can help measure how severe gum disease is and how well treatment works. Researchers will compare healthy people, those with mild to severe gum disease, and smokers with severe gum disease. Participants give saliva samples and get a dental exam, and those with gum disease receive standard treatment. The goal is to find a simple, non-invasive way to diagnose and monitor gum disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 104 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide written informed consent. * Systemically healthy (no history of diabetes mellitus, immunodeficiency, malignancy, or other systemic conditions that could affect periodontal status). * Have a minimum of 20 natural teeth (excluding third molars). * No antibiotic therapy or periodontal treatment in the last 6 months. For Healthy Control Group: No clinical attachment loss. Probing depth ≤ 3 mm. No radiographic evidence of bone loss. Low gingival and plaque index scores. For Mild Periodontitis Group: Diagnosed with Stage I or II periodontitis according to the 2018 AAP/EFP classification. Clinical attachment loss of 1-4 mm. Radiographic bone loss of ≤15-33%. Non-smoker. For Severe Periodontitis Group: Diagnosed with Stage III or IV periodontitis according to the 2018 AAP/EFP classification. Clinical attachment loss ≥ 5 mm. Radiographic bone loss to the mid-advanced level of the root. Non-smoker. For Severe Periodontitis with Smoking Group: Meets all criteria for the Severe Periodontitis Group. Regular smoker (at least 10 cigarettes per day for a minimum of 5 years). Exclusion Criteria: * Fewer than 20 natural teeth (excluding third molars). * Presence of any systemic disease (e.g., diabetes mellitus, immunological disorders, cancer). * Use of antibiotics or receiving periodontal treatment in the last 6 months. * Pregnancy or lactation. * For non-periodontitis groups (Healthy Control): Any signs of periodontitis. * For periodontitis groups (all): History of smoking cessation for at least 5 years (must be either a current regular smoker or a never-smoker, depending on the group definition).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic periodontitis (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic periodontitis periodontal disorder periodontitis Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic periodontitis (disorder) Periodontal disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Erzincan Binali Yıldırım University Faculty of Dentistry

    RECRUITING

    Erzincan, Erzincan, 24002, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.